On March 15, 2025, at the 10th China Pharma & Healthcare Conference and Fair (2025 CPHCF), 聯邦R阿莫仙R (Amoxicillin) (Amoxicillin Capsules) was listed as one of the 「2024–2025 Best-Selling Products in China』s Pharmaceutical Retail Market」 and won the 「2024–2025 CPHCF Award」.

From March 10 to 14, 2025, Zhuhai United Laboratories Co., Ltd. passed the official GMP inspection by Brazil』s ANVISA for its sterile bulk medicine line, injecting strong momentum into the Group』s strategic expansion into the South American market.

On January 23, 2025, the marketing registration application for Semaglutide Injection, submitted by Zhuhai United Bio-Pharmaceutical Co., Ltd., was officially accepted by the National Medical Products Administration (NMPA). This is the products variety declared by The United Laboratories following the company』s successful inclusion in the NMPA』s pilot program for segmented production of biological products.